

Estela Pineda-Losada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9909303/publications.pdf>

Version: 2024-02-01

36
papers

1,582
citations

759055

12
h-index

526166

27
g-index

36
all docs

36
docs citations

36
times ranked

3215
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. <i>Cancers</i> , 2022, 14, 2393.	1.7	8
2	Is IDO1 an adequate target for treatment in glioblastoma?. <i>Journal of Clinical Oncology</i> , 2022, 40, e14039-e14039.	0.8	0
3	Safety and efficacy of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2060-2060.	0.8	0
4	RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP ⁺ negative Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 645-655.	3.2	5
5	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , 2021, 12, 1503.	5.8	45
6	SEOM clinical guideline for management of adult medulloblastoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 940-947.	1.2	6
7	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. <i>Journal of Clinical Medicine</i> , 2021, 10, 2131.	1.0	13
8	Development of Randomized Trials in Adults with Medulloblastoma ² —The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	1.7	8
9	MET inhibitors in cancer: pitfalls and challenges. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 73-85.	1.9	16
10	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6600-6609.	3.2	10
11	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	0.6	64
12	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	5.8	150
13	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	3.2	128
14	Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 779-780.	1.4	1
15	A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETH021).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3123-TPS3123.	0.8	0
16	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3076-3076.	0.8	0
17	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab ² . <i>Neuro-Oncology Practice</i> , 2017, 4, 15-23.	1.0	6
18	Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. <i>Tumor Biology</i> , 2017, 39, 101042831770550.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanineâ€DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	0.8	110
20	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	2.9	56
21	Pseudoprogression as an adverse event of glioblastoma therapy. <i>Cancer Medicine</i> , 2017, 6, 2858-2866.	1.3	44
22	A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples. <i>PLoS ONE</i> , 2017, 12, e0170632.	1.1	100
23	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 66-66.	0.8	0
24	Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13526-e13526.	0.8	0
25	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016, 1, e000032.	2.0	7
26	LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET. <i>Molecular Carcinogenesis</i> , 2016, 55, 411-419.	1.3	11
27	Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy. <i>Annals of Hematology</i> , 2016, 95, 665-666.	0.8	2
28	Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapyâ€A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13515-e13515.	0.8	1
29	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14552-e14552.	0.8	0
30	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3033-3033.	0.8	0
31	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	0.9	735
32	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2015-2015.	0.8	25
33	Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3048-3048.	0.8	5
34	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9069-9069.	0.8	15
35	Clinical outcomes in BRAFV600-mutant metastatic melanoma with sequential treatment with immunotherapy and BRAF inhibitors or vice versa.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20030-e20030.	0.8	0
36	Do we need adjuvant therapy in rectal cancer with complete pathologic response (ypTON0) after induction chemoradiation and laparoscopic mesorectal excision?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3536-3536.	0.8	1